December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

234.00 -2.56 (-1.08%)
Streaming Delayed Price Updated: 1:26 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
FDA Approves Sanofi's Hemophilia Drug ↗
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year. 
Via Benzinga
News headline image
Competitive Analysis In The ATTR-CM Field ↗
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews ↗
 
Via Benzinga
News headline image
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock ↗
Alnylam's Amvuttra wins FDA approval for ATTR-CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity. 
Via Benzinga
News headline image
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗
Best performing large-cap stocks last week: Alnylam Pharma up 16%, Roku up 14%, Elbit Systems up 13%, Venture Global up 12%, Boeing up 11%. Are they in your portfolio? 
Via Benzinga
News headline image
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio ↗
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
News headline image
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps ↗
Alnylam's Amvuttra receives FDA approval for ATTR-CM, expanding its use and securing broad insurance coverage as global regulatory reviews continue. 
Via Benzinga
News headline image
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Alnylam Delivers a Big Q4 Earnings Beat ↗
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress. 
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.